Best Online Retatrutide Providers: We Checked 21 Services

By The RX Index Editorial Team · Last verified October 2026

There is no FDA-approved retatrutide to buy online. Searching for the best online retatrutide providers? We checked 21 services' public pages and found no retail offer. FDA says it cannot be compounded. The documented U.S. paths are a Lilly trial or a doctor-led expanded-access request—not an online order. (FDA; Lilly)

Two things change what you should do next:

• If a website is selling you retatrutide for personal use, that's a warning sign, not a perk. Below, we show who FDA and Lilly have gone after.
• If you want an available weekly shot to discuss with a clinician, tirzepatide (Zepbound) acts on two of retatrutide's three targets. We priced it below. (Zepbound label; Lilly)

So what kinds of sellers have FDA's letters named, and what does the closest approved option cost? Both tables are coming up.

RX Index Decision Verdict: Retatrutide isn't a routine online prescription. Choose the medical path first, then the provider. Best for: a Lilly trial if you match an enrolling study · expanded access if your doctor thinks you meet Lilly's strict rules · tirzepatide (Zepbound) if you want to discuss an FDA-approved option that acts on two of the same targets. Not ideal for: anyone hoping to buy retatrutide as a routine online prescription or a research vial for personal use. The factor that matters most: whether the medicine and care are part of a verified Lilly trial or authorized expanded-access process. A low price, a lab report, or the words "503A pharmacy" don't change that.

Already took something labeled retatrutide and feeling unwell? Jump to what to do now.

Best online retatrutide providers: our 21-provider check

We found no retail retatrutide offer on the public pages checked for these 21 services on October 16, 2026. Three explicitly say they do not offer it. Ro discusses trial access; its pricing page and the other services' pages do not list a retail offer. Those are different findings, so we label them.

We read the official pages linked below, not private intake screens or every page on every site. "Says so in writing" means the company states it doesn't offer retatrutide. "Not listed" means it was absent from the linked pages—not that we proved everything the company does. Before paying, use the questions to ask the clinic below.

Public pages checked October 16, 2026. This is a list of services we checked, not a list of retatrutide sellers. Medicine examples are not a complete menu or a claim that every listed brand is approved for weight loss. LillyDirect is Lilly's medicine-access channel, not a telehealth prescriber.

Several of these companies publish articles about retatrutide. An article about a medicine isn't an offer to sell it.

Why the big names don't sell it

• There's nothing approved to sell. Retatrutide is still being tested. Lilly says it plans to ask the FDA for approval in the first quarter of 2027 (Lilly, July 23, 2026).
• Pharmacies can't compound it. FDA says retatrutide "cannot be used in compounding under federal law" (FDA).
• Medical access is not a retail sale. Lilly warns against consumer retatrutide sales. Its separate medical-information page describes a narrow, physician-led expanded-access process—not an online product offer. (Lilly; Lilly Medical)

A professional-looking website doesn't change those rules. The question is what the service can actually provide.

If you came here hoping to find treatment soon, you're not out of options. The right GLP-1 provider isn't the same for everyone. It depends on your state, your insurance and its drug list, whether you want FDA-approved or compounded, a shot or a pill, and your budget. Since retatrutide isn't one of the choices yet, use The RX Index's Find My GLP-1 Path tool to see which available path fits before you choose. It's free, takes about 2 minutes, and needs no signup.

Who is selling retatrutide online, then?

The FDA letters we reviewed name research-peptide websites, online sellers of compounded drugs, an ingredient distributor, and an outsourcing facility. We checked 21 letters dated December 2024 through August 2026. Lilly also filed the 11 lawsuits described below in August and October 2026. These records show past enforcement actions, not who is still selling retatrutide today.

A warning letter sets out violations FDA identified and asks the company to address them. It isn't a court ruling. These are the 21 letters we reviewed—not a complete census of every retatrutide letter FDA has issued.

The 21 FDA warning letters we reviewed that name retatrutide, December 2024 to August 2026 (checked October 16, 2026). Source links are in the full list.

See all 21 letters

Lilly's lawsuits. On August 12, 2026, Lilly announced six lawsuits against a med spa, a compounding pharmacy, and four peptide sellers in California and Texas (Lilly). On October 8, 2026, it filed five more, against American Peptides, Cenexa Labs, LiveWell Peptides, MedShape Weight Loss Clinic, and Medrein Health & Aesthetics. These are filing counts and allegations, not a count of active cases or court findings. Lilly also says it reported more than 14,000 retatrutide-related websites, ads, social posts, and product listings to online platforms—not 14,000 product listings alone. See our retatrutide lawsuits guide for the separate legal timeline.

The 21 service names in our comparison do not match the recipients or defendants listed here. That is not a check of every related company, or a claim that these services have no other enforcement history. One important limit: FDA's Darmerica letter says the company's corrective steps on retatrutide appeared adequate. A historical letter is not proof of a current sale. (Darmerica letter)

Where people actually get it. In a review of U.S. health records posted in August 2026, 378 people had a documented non-trial source. Most got it from online or telehealth vendors (57%) or compounding pharmacies (29%) (nference preprint, not yet peer reviewed).

What's been reported so far. These reports don't prove a product caused harm, but they're why "unknown vial" is a real worry:

• Public Citizen counted at least 14 reported hospitalizations involving retatrutide in FDA's adverse-event database as of June 2026 (Public Citizen).
• CBS News reported two unverified death reports involving products claiming to be retatrutide; causation was not established.
• In its June 19, 2026 alert, Victoria, Australia reported six cases of acute liver injury since January in people using unapproved products labeled Retatrutide, Reta, R-10, or R-20. The alert raised a possible contaminant and said testing was underway; it did not establish the cause. (Victoria Department of Health)

Is it legal to buy retatrutide online?

Not as a normal U.S. prescription purchase. Retatrutide has no FDA approval, and FDA says it cannot be compounded under federal law. A clinical trial or authorized expanded-access request is a different medical process—not permission for a seller to take retail orders. (FDA; expanded access)

Think of these as three locked doors to a retail treatment purchase:

Can your doctor prescribe it off-label? No. "Off-label" means using an approved drug in a way its label doesn't list. Retatrutide has no approval and no approved label, so that is not a way to prescribe it. A doctor can instead assess a trial or expanded-access request. (FDA)

Does a pharmacy license make it okay? No. A licensed pharmacy is a good sign for the drugs it's allowed to make. It doesn't make retatrutide one of them. For the full legal walk-through, see why retatrutide can't be compounded.

Does a lab report (certificate of analysis) make it safe? No—not by itself. A certificate of analysis, or COA, reports tests on a sample. It does not by itself prove what is in your vial or how it was handled. Some reports include sterility testing; none is FDA approval or permission to sell retatrutide for treatment. Buying a "research use only" vial to inject is like buying a car part stamped "for display only" and bolting it onto your brakes. The label doesn't make that safe, and it does not shield a seller whose product is marketed for human use. (FDA; FDA warning letter)

There's also an early health-records comparison, but it does not test what's inside those vials. In the August 2026 review, people recorded as using non-trial "compounded" retatrutide lost about 7.2% of their weight at 6 to 12 months, compared with 15.5% for the trial group. That trial group included people enrolled to receive retatrutide or placebo, not a confirmed retatrutide-only group. The groups could also differ in dose, treatment use, and health. The study is observational, not peer reviewed, and written by employees of the company that ran it, so treat it as a signal, not proof of product quality or equivalent results. (nference preprint)

You'll also see retatrutide called "GLP-3." That's a nickname, not a real drug class (what "GLP-3" actually means).

Retatrutide Offer Checker: is the offer in front of you real?

Retatrutide access needs a verified study team or a treating doctor working through expanded access. A paid visit is not the same as buying the drug. Answer five quick questions about the offer you saw. This checker helps you spot a retail-treatment offer or find what still needs checking; it cannot verify a company or approve access. (Lilly; FDA)

Here's a worked example. Say a site sells "Reta 10 mg, research use only" with free bacteriostatic water and a dosing chart, and you'd pay $80 at checkout. You'd answer: a research website, yes you pay, "research use only." The checker says not a lawful retail treatment offer. That finding comes from the product and sale described—not just the website being a peptide shop. FDA has warned sellers of research-use retatrutide marketed for people. (FDA warning letter)

Ask this before you pay anyone. If a clinic or site still says it can help, copy this and ask for an answer in writing:

Before I pay, please confirm in writing: Which exact medicine and service am I paying for? If this is about retatrutide, is it an official clinical trial or a doctor-led expanded access request from Lilly? What's the study's NCT number, or who is the treating physician? If a pharmacy will dispense medicine, what is its legal name and state license number? What are the separate charges for the visit, medicine, tests, and shipping, and what happens to each charge if treatment doesn't go ahead?

The team should be able to explain the process and separate any care charges from the drug. For expanded access, Lilly says it supplies the medicine at no cost. Vague answers mean you still need confirmation—not that this page has proved a company broke the law.

The only real ways to get retatrutide today

The documented medical paths to Lilly-made retatrutide are a clinical trial or Lilly's single-patient expanded access program, which only your treating doctor can request. Both are narrow, and neither is an online order. A program listing does not guarantee a place or supply. (Lilly Medical; Lilly Trials)

Clinical trials: ask the study team

One trial that Lilly lists as enrolling on October 16, 2026 is SYNERGY-Outcomes. That status does not guarantee an opening at every site. It studies adults with high-risk metabolic dysfunction-associated steatotic liver disease (MASLD, a liver condition caused by fat buildup). People are randomly given retatrutide, tirzepatide, or placebo. It lasts about 4.5 years, with about 30 visits (Lilly trial page).

That's a serious commitment for a specific liver condition. It isn't a shortcut to a weight-loss shot. If it fits you, the trial page lists a study nurse line.

For more studies and their reported status, see our retatrutide clinical trials tracker. Don't stop a medicine you take now to try to qualify for a trial without talking to your prescriber and the study team.

Expanded access: start with your treating doctor

Expanded access is a legal way for one patient to get an unapproved drug outside a trial. Lilly opened one for retatrutide. According to Lilly, you must meet all five of these (Lilly Medical, reviewed August 26, 2026):

1. You're 18 or older.
2. Your body mass index (BMI)—a measure based on height and weight—is 35 or higher despite taking, and tolerating, the highest available dose of a long-term weight-loss medicine as prescribed.
3. You have at least two serious or life-threatening conditions caused or worsened by obesity, and they're being treated.
4. You can't join a retatrutide or similar trial, because you don't qualify or there's no site you can reasonably reach.
5. You and your doctor have talked through every standard option, including weight-loss surgery. (Talked through, not had.)

A medical reason that rules out retatrutide—a contraindication—also excludes a patient. Meeting the five rules does not guarantee access. The registry lists NCT07629401 as "Available" (record updated August 6, 2026), but that is a program status, not an individual approval.

Your doctor makes the request by calling the Lilly Answers Center at 1-800-545-5979. You can't apply yourself. Lilly says it provides the drug at no cost, but it reviews each request case by case and availability depends on location and supply. The physician must handle FDA authorization, ethics-board approval, informed consent, and follow-up requirements. Lilly does not ship the drug directly to patients through this program. (Lilly Medical; FDA)

FDA notes that expanded-access costs usually aren't covered by private insurance or Medicare. Visits, tests, and ethics-board review can have separate charges even when Lilly supplies the drug free. Ask the treating team and your own plan what you would owe. (FDA)

Here's a simple way to start the talk with your doctor:

I read about Lilly's expanded access program for retatrutide. Could we look at my treatment history and decide whether a clinical trial, an expanded access request, or an approved medicine is the right next step for me?

For the full checklist to bring to that visit, see Lilly's retatrutide early access rules.

What's the closest thing you can start online now?

Tirzepatide, sold as Zepbound for weight loss, acts on two of retatrutide's three targets: GIP and GLP-1. That makes it a close match in how it works, not proof that it produces the same results. It isn't retatrutide, and a licensed clinician decides whether it fits you, but it is an FDA-approved option. (Zepbound label; Lilly)

Here's the honest part: Zepbound is not retatrutide. Lilly's head-to-head trial, TRIUMPH-5, is comparing the two. If you only want the triple-hormone drug, nothing here will satisfy you, and that's okay. But if what you really want is an approved treatment to discuss now, this is where to look. For how the two compare on what's known so far, see retatrutide vs tirzepatide.

Find your row:

Start with your own clinician first if you're under 18, pregnant or planning a pregnancy, have type 1 diabetes, have a history of an eating disorder, or have anything a medicine's label says rules you out, such as a personal or family history of medullary thyroid cancer or MEN 2. (Zepbound label)

Not sure if you'd qualify at all? For adult weight management, the usual starting point is a BMI of 30, or 27 with a weight-related condition like high blood pressure. That is not the full eligibility check, and it does not apply to every use of every product. A clinician confirms the rest. (Zepbound label; Foundayo label)

What the closest options really cost

Through Ro, you pay two separate charges: a membership and the medicine. A first-month example is $338: $39 membership plus a $299 Zepbound KwikPen pack at the starting strength. That pack contains four weekly doses—28 days, not a calendar month. On the ongoing monthly membership plan, add $149 to each medication price below. These are published-price examples, not a checkout quote. (Ro pricing; Zepbound)

Think of it as the whole receipt, not the sticker price. Our True Monthly Cost measure includes medicine plus required membership, consultation, labs, and shipping. The table below calculates the published medicine-plus-membership amount. It isn't a complete personal total where a checkout charge remains unknown.

Ro cash prices checked October 16, 2026. First-month examples use the advertised $39 introductory membership. Later columns combine one listed medication fill with one monthly membership charge or an annual-plan monthly equivalent; they do not show a single invoice or a full-year total. Sources: Ro pricing, Zepbound terms, and Foundayo terms.

What to know before you trust these numbers:

• The 12-month plan is paid up front. $74 a month times 12 is $888 for membership, billed at once (our math from Ro's listed rate). It's not a $74 monthly bill. Ro says the chosen ongoing plan follows the $39 first month. The $888 is a full-term membership prepayment, not an extra amount we have assumed is due with your first medication order. A monthly equivalent does not mean unused months are refundable. (Ro pricing)
• The $449 Zepbound offer has a deadline between refills. Ro requires the refill check-in within 45 days of the last delivery. Without the offer, 7.5 mg is $499 for the medicine and 10–15 mg is $699. With $149 monthly membership, those amounts become $648 or $848, not $598. (Ro's Zepbound terms)
• Foundayo also has offer conditions. Ro's pricing page says to sign up by December 31, 2026 for the 2.5 mg and 5.5 mg offers; its Foundayo page describes those prices as lasting through that date. Confirm the renewal price rather than assuming signup locks in the lower price afterward. At 14.5 or 17.2 mg, the $299 refill offer requires the check-in within 45 days of the last delivery; without it, medicine is $349, or $498 with monthly membership. The 9 mg listed price is $299 without that higher-strength refill condition. (Ro pricing; Foundayo terms)
• Your dose sets the price. Dose changes follow the label's schedule and your clinician's call, not this table. A dash means we did not model that payment stage—not that the medicine is free or that every new member starts at that strength.
• Necessary lab testing is included in Ro's membership. Ro also lists the clinical evaluation and ongoing care among membership services. The table does not assume that outside care, shipping, or supplies have a zero charge where the selected checkout has not confirmed them. (Ro pricing)
• A fill and a membership month are different units. The Zepbound pack is a four-week supply; membership is billed by month or prepaid term. Do not multiply one row by 12 and call it a complete year of continuous treatment.
• Insurance can change everything. If your plan covers the medicine, your cost may be far lower. Ro says its medication cash prices match LillyDirect, NovoCare, and TrumpRx; that comparison does not include Ro's separate membership. A prescriber you already have may help you use a manufacturer channel without adding that membership.

If you have commercial insurance, check it before you pay cash. Ro's free check covers the Ozempic, Wegovy, and Zepbound autoinjector pens. It does not check the Wegovy pill, Foundayo pill, or Zepbound KwikPen priced above. It's a coverage report, not a prescription or a submitted prior-authorization request. A licensed clinician still decides what's right for you. (Ro's checker)

Paying cash for a brand-name medicine, or want a pill? Ro lists both, with the medicine billed separately from the membership: $39 for the first month, then $149 on the monthly plan or as low as $74 a month with the annual plan paid upfront. Compare that separate fee with using your own clinician and LillyDirect. Ro's published offer says the $39 is refunded if you are not eligible for GLP-1s. For more on how Ro works, see our Ro review.

If you'd consider compounded tirzepatide instead

Compounded tirzepatide is not FDA-approved, not retatrutide, and not a generic Zepbound. FDA does not review compounded drugs for safety, effectiveness, or quality before patients get them. Price alone does not create a legal exception for a copy of an available brand. A patient-specific prescription and the product must meet the current compounding rules. (FDA; current compounding policy)

For example, FDA describes an exception under the patient-specific pharmacy rules when the prescriber determines that a change makes a significant difference for an identified patient. That is a medical decision, not a box to tick for a cheaper price. FDA lists tirzepatide as no longer in shortage. A clinician review alone does not make every compounded offer lawful. (FDA policy)

Embody is a cash-pay program for compounded semaglutide and tirzepatide. On October 16, 2026, its homepage advertised compounded tirzepatide "from $119/month," with no membership fee. Its homepage describes 4-, 12-, 24-, and 52-week plans. Its written terms (last updated April 24, 2026) list different prices: $149 for the first month of tirzepatide, then $399 a month on one plan, or $299 a month on a flat plan. (Embody terms; refund policy)

The newer refund policy matters. Dated August 25, 2026, it says payments are generally final, but promises a refund for the unused part of the paid term if its provider finds you medically ineligible, less services already provided. Cancellation must be at least 72 hours before the next billing date. Do not assume ordinary cancellation earns a prorated refund. (Embody refund policy)

So confirm two numbers at checkout: what's due today, and what renews. Also note that a "4-week" plan isn't a calendar month. Embody says clinician review comes after checkout, so paying is not the same as being approved for a prescription. Get the refund terms for your selected plan before paying.

Embody's terms say its affiliated providers do not contract with health plans; this is a cash-pay offer. If you want to use insurance for an approved medicine, start with your plan or Ro's coverage check—not this compounded program. A price with no separate membership can be simpler to compare, but only once you know the full prepaid amount, renewal price, and medical fit. (Embody terms) Read our full Embody review and how compounded and brand-name GLP-1s differ.

If your clinician identifies a patient-specific need for compounded tirzepatide and the prescription can meet current law, here is Embody's offer to check. Its advertised price is not a guarantee of your eligibility, your total, or the lawfulness of a particular prescription.

Already have a clinician who can help?

You don't need an online membership just to talk about treatment. Ask your current doctor what they can prescribe and manage. Then compare an online program only for what you still need.

Should you wait for retatrutide?

There is no confirmed FDA approval date, launch date, or commercial price to plan around. Lilly said it plans to file for FDA approval in the first quarter of 2027; filing is not approval. If you only want retatrutide, discuss waiting with your clinician rather than assuming your health can wait. (Lilly, July 23, 2026)

If you do wait, make it a decision with a date. Set a reminder for April 2027 to see whether Lilly has filed. Ignore sellers' launch countdowns; filing does not mean pharmacies can start filling routine prescriptions. For timing details, see retatrutide availability, and for price forecasts, see retatrutide cost predictions.

Already bought or used retatrutide from a website?

Call 911 for trouble breathing, collapse, a seizure, or someone who can't be woken up. For a possible exposure or a concern about what you took, call Poison Control at 1-800-222-1222 (free, 24/7). You do not need to wait for severe symptoms to ask for help. (Poison Control)

Don't be hard on yourself. Tell the clinician or poison specialist exactly what you used, when, and how much, and keep the vial and label. Do not use an unverified product again before getting that advice. If your medicine is part of an authorized trial or expanded-access program, contact your study team or treating doctor; this section is not an instruction to stop authorized study treatment.

You can report a side effect to FDA MedWatch. You can report the seller through FDA's BeSafeRx page or to Lilly at 1-800-545-5979.

Trial side-effect data may not describe an unknown vial, but it's useful background: retatrutide side effects from the trials.

How we checked

On October 16, 2026, we read the official service pages linked in the comparison, FDA's statements and the 21 warning letters above, plus Lilly's medical and trial pages. We didn't buy any product, join any program, or test any medicine. This was a public-page check, not a complete search of every company's site or private intake.

The RX Index is the independent GLP-1 decision resource that scores telehealth providers and treatment paths on clinical legitimacy, care quality, transparency, access, and cost, so readers can choose the path that fits their situation.

What we actually verified — October 2026 Source checks completed October 16, 2026.

• FDA status and compounding: FDA's unapproved GLP-1 safety page, current compounding policy, and the retatrutide passages in all 21 linked warning letters. We did not establish that this is every letter FDA has issued.
• Lilly: its consumer page on retatrutide (updated September 2026), its July 23, 2026 filing plan, its August 12, 2026 lawsuit announcement, its expanded access page (reviewed August 26, 2026), and the SYNERGY-Outcomes and TRIUMPH-5 trial pages. October lawsuit filing dates and defendants were checked against court records.
• Registry: ClinicalTrials.gov record NCT07629401 shows expanded access as "Available" (record last updated August 6, 2026).
• Providers: the linked public pages for all 21 services in our table. Explicit statements and missing menu listings are labeled separately; neither is a test of care quality or product supply.
• Prices: Ro's pricing page, Zepbound and Foundayo offer terms, and insurance checker; Embody's homepage, April 24 terms, and August 25 refund policy. These are published prices and policies, not a checkout quote. Necessary Ro labs are included; refill offers have conditions.
• Conflicts we didn't hide: Lilly's consumer page says retatrutide is available only through trials, while Lilly Medical describes expanded access. We used the specific program page for that exception. Embody's homepage price and written terms don't match.
• What we couldn't confirm: private accounts or checkout charge dates, every state's availability, every trial site's openings, or any individual's eligibility. No product's contents were tested.

We don't score retatrutide sellers. Our RX Index Score rates providers of available treatments on six factors: clinical legitimacy and safety (25%), care and support model (20%), medication options and fit (15%), transparency and honest terms (15%), value / true cost (15%), and access and speed (10%). See our methodology.

Retatrutide provider questions, answered

Is retatrutide legal in the US?

It is not available for ordinary U.S. retail treatment sales, and FDA says it cannot be compounded. It remains investigational. A Lilly clinical trial or authorized physician-led expanded access is different from buying a retail product. (FDA; Lilly Medical)

Do I need a prescription, or is retatrutide a supplement until it's approved?

It's not a supplement. It's an investigational drug, not a product for an ordinary retail prescription. A "research use only" label does not authorize it for treatment; documented medical access is through a trial or expanded-access process. (FDA; Lilly Medical)

How can a clinic offer retatrutide if it isn't approved?

A clinic may be discussing a trial, a doctor-led expanded-access request, or a different medicine. That is not the same as selling retatrutide as a routine prescription. Ask for the exact process in writing; a clinic's credentials alone do not validate the product. (Lilly Medical; FDA)

How can I know my vial is from a tested batch?

A lab report alone cannot establish that the vial you received matches the tested sample or was handled correctly. Some reports include sterility tests, but even a detailed report is not FDA approval or a lawful medical-access process. Do not treat a COA as permission to use a research vial. (FDA)

Which is cheaper, retatrutide or tirzepatide?

Retatrutide has no announced commercial price, so there is no retail price to compare. Lilly supplies its expanded-access drug at no cost, but care can still cost money. A starting-strength Zepbound KwikPen pack is $299 through Ro for four weekly doses, plus membership; the introductory medicine-plus-membership example is $338. (Lilly Medical; Ro, checked October 16, 2026)

Is retatrutide available in the USA or Canada?

Lilly says retatrutide has not been approved by any regulatory agency, which includes the U.S. and Canada. A trial listing is not the same as retail availability, and any expanded-access request depends on the country and program. This page's retail-law discussion is about the U.S. (Lilly; Lilly Medical)

Does Hims, Ro, or Eden offer retatrutide?

We found no retail retatrutide offer on the linked Hims, Ro, or Eden pages checked October 16, 2026. That is a public-page finding, not a claim about every private conversation or service. Ro's article discusses trial access but omits Lilly's documented expanded-access exception; the comparison above labels that limit.

Can my doctor prescribe retatrutide off-label?

No. Off-label prescribing applies to approved drugs. Your treating doctor can assess a trial or ask Lilly about expanded access, but the program's criteria and required authorizations still apply. (FDA; Lilly Medical)

Is compounded retatrutide legal?

No. FDA says retatrutide cannot be used in compounding under federal law. For more, see compounded retatrutide.

Will insurance pay for retatrutide or expanded access?

There is no approved retail retatrutide product. Lilly says it supplies the expanded-access medicine at no cost, but FDA says expanded-access costs usually are not covered by private insurance or Medicare. Ask your treating team and plan about visits, tests, and other charges; free medicine does not mean free care. (Lilly Medical; FDA)

Should I pay for an online visit just to ask for retatrutide?

Don't pay on the assumption that the visit includes retatrutide. A clinician may discuss available medicines or assess whether a trial or expanded-access request is appropriate. Ask what service the fee buys and what happens if treatment or access does not go ahead.

Is "GLP-3" the same as retatrutide?

"GLP-3" is a nickname, not a recognized drug class. Retatrutide acts on three hormone receptors: GIP, GLP-1, and glucagon. A seller using "GLP-3" has not established that the product is genuine retatrutide or authorized for treatment. (Lilly)

Still not sure which GLP-1 path fits you? Take The RX Index's free Find My GLP-1 Path quiz — about 2 minutes, no signup.

Sources

Checked October 16, 2026 unless noted.

• FDA — FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
• FDA — Expanded Access: Information for Patients
• FDA — 21 warning letters naming retatrutide, linked in the table above (December 10, 2024 – August 24, 2026)
• Eli Lilly — What to know about retatrutide (updated September 2026)
• Eli Lilly — Retatrutide successful in two additional Phase 3 obesity trials; BLA planned Q1 2027 (July 23, 2026)
• Eli Lilly — Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market (August 12, 2026)
• Lilly Medical — Is there an expanded access program for retatrutide? (reviewed August 26, 2026)
• ClinicalTrials.gov — Pre-approval Expanded Access of Retatrutide, NCT07629401 (record updated August 6, 2026)
• Lilly Trials — SYNERGY-Outcomes, NCT07165028
• Court records — October 8, 2026 complaints and docket entries for the five named defendants, linked in the lawsuits paragraph above. The allegations are not findings of liability.
• Public Citizen — Hospitalizations, enforcement gaps, and influencers tied to unapproved retatrutide products (June 16, 2026)
• CBS News — Retatrutide adverse-event reporting (direct reporting)
• Victoria Department of Health — Toxicity linked to unapproved product labelled retatrutide (June 19, 2026)
• Murugadoss et al. (nference) — Accelerating Use of Unapproved Retatrutide Is Associated with Weaker Weight Loss and Increased Cardiovascular Symptoms (preprint, August 18, 2026, not peer reviewed)
• Ro — Weight loss pricing and How to get retatrutide (updated August 27, 2026)
• PlushCare — Retatrutide prescription page
• FormBlends — Retatrutide for weight loss (updated September 27, 2026)
• TrimRx — Is retatrutide FDA approved? (June 22, 2026)
• Embody — Homepage, Terms and Conditions (April 24, 2026), and Refund Policy (August 25, 2026)
• FDA — Current GLP-1 compounding policy and Off-label use of approved drugs
• Product labeling — Zepbound, Wegovy injection and tablets, and Foundayo
• Ro — Zepbound offer terms, Foundayo offer terms, and Free insurance checker
• Lilly Trials — TRIUMPH-5, NCT06662383
• Poison Control — When to call 911 or Poison Control
• Provider menu sources — each service's official public page is linked in the 21-service comparison.